Decoy Therapeutics (NASDAQ:DCOY – Get Free Report) and Hepion Pharmaceuticals (NASDAQ:HEPA – Get Free Report) are both small-cap manufacturing companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, profitability, earnings and risk.
Risk & Volatility
Decoy Therapeutics has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, Hepion Pharmaceuticals has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500.
Insider & Institutional Ownership
11.9% of Decoy Therapeutics shares are owned by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. 1.7% of Decoy Therapeutics shares are owned by insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Decoy Therapeutics | 1 | 0 | 1 | 0 | 2.00 |
| Hepion Pharmaceuticals | 0 | 0 | 0 | 0 | 0.00 |
Decoy Therapeutics currently has a consensus target price of $30.00, indicating a potential upside of 380.38%. Given Decoy Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Decoy Therapeutics is more favorable than Hepion Pharmaceuticals.
Valuation & Earnings
This table compares Decoy Therapeutics and Hepion Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Decoy Therapeutics | N/A | N/A | -$12.52 million | ($106.90) | -0.06 |
| Hepion Pharmaceuticals | N/A | N/A | -$48.93 million | ($72.15) | 0.00 |
Decoy Therapeutics is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Decoy Therapeutics and Hepion Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Decoy Therapeutics | N/A | -395.42% | -193.30% |
| Hepion Pharmaceuticals | N/A | -812.56% | -207.31% |
Summary
Decoy Therapeutics beats Hepion Pharmaceuticals on 7 of the 11 factors compared between the two stocks.
About Decoy Therapeutics
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
About Hepion Pharmaceuticals
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Receive News & Ratings for Decoy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Decoy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
